Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Patients with heart failure (HF) and atrial fibrillation (AF) have higher circulating levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) than HF patients without AF. There is uncertainty about the prognostic importance of a given concentration of NT-proBNP in HF patients with and without AF. We investigated this question in a large cohort of patients with HF and reduced ejection fraction. Methods and Results: We studied 14 737 patients with HF and reduced ejection fraction and a measurement of NT-proBNP at time of screening, enrolled in either the PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) or the ATMOSPHERE trial (Aliskiren Trial to Minimize Outcomes in Patients With Heart Failure), of whom 3575 (24%) had AF on their baseline ECG. Median (Q1, Q3) levels of NT-proBNP were 1817 pg/mL (1095–3266 pg/mL) in those with AF and 1271 pg/mL (703–2569 pg/mL) in those without ( P <0.0001). Patients with AF were older (67 versus 62 years), had worse New York Heart Association class (III/IV; 36% versus 24%), and experienced fewer previous HF hospitalizations (52% versus 61%) or myocardial infarction (30% versus 46%); all P <0.001. We categorized patients with and without AF into 5 NT-proBNP bands: <400, 400 to 999 (reference), 1000 to 1999, 2000 to 2999, and ≥3000 pg/mL. For the primary composite outcome of cardiovascular death or HF hospitalization, event rates differed for patients with and without AF in the lowest band (<400 pg/mL; 8.2 versus 5.0 per 100 patient-years), but not for the higher bands (400–999 pg/mL, 7.4 versus 7.7 per 100 patient-years; 1000–1999 pg/mL, 9.8 versus 11.4 per 100 patient-year; 2000–2999 pg/mL, 13.5 versus 13.4 per 100 patient-years; ≥3000 pg/mL, 22.7 versus 23.0 per 100 patient-years). These findings were consistent whether NT-proBNP was examined as a categorical or continuous variable and before and after adjustment for other prognostic variables. We found similar results for the components of the composite outcome and all-cause mortality. Conclusions: HF and reduced ejection fraction patients with AF had higher NT-proBNP than those without AF. However, above a concentration of 400 pg/mL (representing most patients in each group), NT-proBNP had similar predictive value for adverse cardiovascular outcomes, irrespective of AF status. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier NCT00853658 (ATMOSPHERE) and NCT01035255 (PARADIGM-HF).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationState of the art: using natriuretic peptide levels in clinical practice
Maisel, A., Mueller, C., Adams, K., Anker, S. D., Aspromonte, N., Cleland, J. G. F., Cohen-Solal, A., Dahlstrom, U., DeMaria, A., Di Somma, S., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.07.014 · Cited by 839
Roberts, E., Ludman, A. J., Dworzynski, K., Al-Mohammad, A., Cowie, M. R., McMurray, J. J. V., Mant, J., & on behalf of the NICE Guideline Development Group for Acute Heart Failure (2015) · BMJ · doi:10.1136/bmj.h910 · Cited by 427
Self-citationMadamanchi, C., Alhosaini, H., Sumida, A., & Runge, M. S. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.08.007 · Cited by 357
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Joubert, M., Manrique, A., Cariou, B., & Prieur, X. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.07.003 · Cited by 81
Docherty, K. F., Shen, L., Castagno, D., Petrie, M. C., Abraham, W. T., Böhm, M., Desai, A. S., Dickstein, K., Køber, L. V., Packer, M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1682 · Cited by 42
“More importantly, none of these prior studies included routine 50 measurement of natriuretic peptides, which are elevated further in patients with AF, 51 compared to those in sinus rhythm.(15) Existing studies cannot, therefore, reliably tell whether 52 resting ventricular rate is an independent predictor of adverse c…”
ResultSelf-citation
Metadata
- Authors
- Kristensen, S. L., Jhund, P. S., Mogensen, U. M., Rørth, R., Abraham, W. T., Desai, A., Dickstein, K., Rouleau, J. L., Zile, M. R., Swedberg, K., Packer, M., Solomon, S. D., Køber, L., & McMurray, J. J. V.
- Venue
- Circulation: Heart Failure
- Published
- 2017-10
- Volume
- 10
- Issue
- 10
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W2763535499
- Cited by
- 76
- References
- 5
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. https://app.cochat.ai/papers/10.1161/circheartfailure.117.004409
- The paper
- Kristensen, S. L., Jhund, P. S., Mogensen, U. M., Rørth, R., Abraham, W. T., Desai, A., Dickstein, K., Rouleau, J. L., Zile, M. R., Swedberg, K., Packer, M., Solomon, S. D., Køber, L., & McMurray, J. J. V. (2017). Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.117.004409
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.